sulforaphane has been researched along with Parkinsonian Disorders in 1 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "However, the disease progression remains unaffected, because of continuous dopaminergic neuron loss." | 1.37 | Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. ( Cuadrado, A; Fernández-Ruiz, J; Hesse, M; Innamorato, NG; Jazwa, A; Rojo, AI, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jazwa, A | 1 |
| Rojo, AI | 1 |
| Innamorato, NG | 1 |
| Hesse, M | 1 |
| Fernández-Ruiz, J | 1 |
| Cuadrado, A | 1 |
1 other study available for sulforaphane and Parkinsonian Disorders
| Article | Year |
|---|---|
Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticarcinogenic Agents; Antioxidants; Basal | 2011 |